Hta / Projects

Second Programme of Community action in the Field of Health 2008-2013
European network for HTA Joint Action [EUnetHTA JA]
The overarching objective of the Joint Action (JA) on Health Technology Assessment (HTA), EUnetHTA Joint Action, including work on relative effectiveness assessment (REA) of pharmaceuticals is to put ...
The overarching objective of the Joint Action (JA) on Health Technology Assessment (HTA), EUnetHTA Joint Action, including work on relative effectiveness assessment (REA) of pharmaceuticals is to put into practice an effective and sustainable HTA collaboration in Europe that brings added value at the European, national and regional level. The JA brings together 34 HTA agencies and institutional producers of HTA and assessments of pharmaceuticals in 24 EU and 1 EEA/EFTA country (as of November 2010). The JA facilitates solutions to overcome barriers to collaboration and facilitates national solutions to deliver context specific reporting of HTA results.
Start date: 01/01/2010 - End date: 01/02/2013

Call: Generate And Disseminate Health Information And Knowledge (Hi-2009)
Topic: Hta
Second Programme of Community action in the Field of Health 2008-2013
European Patients' Forum [EPF_FY2012]
-Vision:
Patient-centred, high quality, equitable healthcare for all patients throughout the EU.
-Mission:
To be the collective patients` voice at EU level, manifesting the solidarity, power and unity...
-Vision:
Patient-centred, high quality, equitable healthcare for all patients throughout the EU.
-Mission:
To be the collective patients` voice at EU level, manifesting the solidarity, power and unity of the EU patients` movement,and provide a strong and united patients` voice to put patients at the centre of EU health policy and programmes.
-Core values/guiding principles as agreed in the Strategic Plan:
- We are patient-centred and right-based
- We combat discrimination on the grounds of illness and address health inequalities from the perspective of patients
- We advocate a holistic approach to healthcare issues that includes the social, economic,cultural, environmental and mental health agenda for patients, carers and families
- We foster the empowerment of patients, carers and their families by breaking down attitudinal barriers and prejudice regarding patients` place in society as equal citizens
- We consult and build consensus within our membership to address the EU policy issues that have an impact on the patient community
- We are an independent organisation, transparent in all our operations-financial, policy,communications
- We are an open and inclusive organisation and strive to ensure that our work also reflects the opinion of potentially marginalised and under-represented patients,carers and families
- We have a strong commitment to gender equality
Additional values informing our work are:
- We foster the meaningful involvement of patients through empowerment by breaking down attitudinal barriers regarding the place of patients in healthcare and society as equal citizens
- We encourage effective,inclusive and sustainable patient organisations throughout the EU
- We are committed to giving a voice to underrepresented patients, including young patients and reaching out to all ethnic and cultural patient groups
- With regard to ethical issues,EPF respects recognised European and International instruments protecting human rights.
Our vision and core values inform EPF`s policy and programme work, external communications and collaboration.
Start date: 01/01/2012 - End date: 01/01/2013

Call: Generate And Disseminate Health Information And Knowledge (Hi-2010)
Topic: Hta
Second Programme of Community action in the Field of Health 2008-2013
Cross-Border Patient Registries Initiative [PARENT]
The overall objective is to support member states in developing comparable and coherent patient registries in fields of identified importance (e.g. chronic diseases, rare diseases, medical technology)...
The overall objective is to support member states in developing comparable and coherent patient registries in fields of identified importance (e.g. chronic diseases, rare diseases, medical technology) with the aim to rationalize and harmonize the development and governance of patient registries, thus enabling analyses of secondary data for public health and research purposes. (Please find the entire text in the accompanying Word document, Annex 1b).
Start date: 01/05/2012 - End date: 01/12/2015

Call: Generate And Disseminate Health Information And Knowledge (Hi-2010)
Topic: Hta
3rd Health Programme (2014-2020)
Promoting Implementation of Recommendations on Policy, Information and Data for Rare Diseases [RD-ACTION]
Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition...
Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition leading to diagnostic delay and inappropriate management including adapted social services, poor health outcomes, social burden, limited knowledge on natural history and pathophysiology leading to an insufficient development of new therapies. The low prevalence and the specificity of RD make that a global, multi-stakeholder approach, intended to gather specific expertise and to build shared strategies is necessary to address these issues.
The general objectives of RD-Action are to:
▪ Support the further development and sustainability of the Orphanet database, the biggest global repository of information on RD
▪ Contribute to solutions to ensure an appropriate codification of RD in health information systems
▪ Continue implementation of the priorities identified in Council Recommendation 2009/C151/02 and the Commission Communication (COM 2008 679) on RD, with a view to ensuring the sustainability of the recommended priority actions and to support the work of the Commission Expert Group on Rare Diseases (CEGRD).
This JA will expand and consolidate the achievements of the former JAs on RD supported by the European Commission: the Orphanet JA and the EUCERD JA. More precisely, this proposal has the ambition to help member states to implement the recommended measures adopted or to be adopted by the CEGRD and to produce the data necessary for countries to do so. Interactions between the production of data at the Orphanet database level and the implementation of policy priorities including codification will be strengthened during this JA.RD-Action large geographical coverage is key to success as it will promote the transfer of European recommendations into national policies and the collection of information and concerns from MS to the CEGRD, thus to the European Commission.

Start date: 01/06/2015 - End date: 31/07/2018

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Hta
3rd Health Programme (2014-2020)
European Network for Health Technology Assessment (EUnetHTA) - Joint Action 3 [EUnetHTA JA3]
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and...
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and health technologies and ensure re-use in regional and national HTA reports and activities, in order notably to avoid duplication of assessments. An overarching objective is to develop a general strategy, principles and proposal for a scientific and technical mechanism of permanent sustainable European Collaboration on HTA in the light of the Directive on CBHC. During the JA3 the collaborative production of structured HTA core information, including rapid HTAs will be structurally implemented and the methodologies and production related information and communication technology infrastructure will be finalised as to stand alone from 2020 onwards. EUnetHTA JA3 will also aim to increase the alignment between HTA reports used for reimbursement decisions and clinical practice guidelines that are used by physicians in daily practice. Additionally, EUnetHTA JA3 will also support more alignment of different processes in the lifecycle of health technologies. For instance, processes on market authorization and HTA of pharmaceuticals could be organised in a more closely aligned fashion which may lead to a timelier and more efficient process promoting earlier patient access to products that have a real added value. EUnetHTA JA3 will also contribute to the discussion on the assessment of the effectiveness and safety of new medical devices as is currently taken place as part of the debate on new European legislation for medical devices. Finally, all these outcomes will contribute to the dissemination of health information and knowledge, thus improving policy-and decision-making in the health systems, which turns into protection of citizens against unsafe or ineffective technologies and improves access to high value health technologies. Ultimately this contributes to imTo be developed
Start date: 01/06/2016 - End date: 31/05/2021

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Hta